Evidence map›Paper›PMID 30427535›Full record

ArticleCancer2019

Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?

Adriana C Vidal, Lauren E Howard, Amanda De Hoedt, Christopher J Kane, Martha K Terris, William J Aronson, Matthew R Cooperberg, Christopher L Amling, Stanislav Lechpammer, Scott C Flanders and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Adriana C VidalDivision of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California.
Lauren E HowardDivision of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California.
Amanda De HoedtUrology Section, Veterans Affairs Medical Center, Durham, North Carolina.
Christopher J KaneUrology Department, University of California-San Diego Health System, San Diego, California.
Martha K TerrisSection of Urology, Veterans Affairs Medical Center, Augusta, Georgia.
William J AronsonUrology Section, Department of Surgery, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California.
Matthew R CooperbergDepartment of Urology, University of California-Los Angeles Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Christopher L AmlingDivision of Urology, Oregon Health Sciences University, Portland, Oregon.
Stanislav LechpammerMedical Affairs Oncology, Pfizer, Inc, San Francisco, California.
Scott C FlandersHealth Economics and Clinical Outcomes Research-Oncology, Astellas Pharma, Inc, Northbrook, Illinois.
Stephen J FreedlandDivision of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California.
Cedars-Sinai Medical Center · USUniversity of California, Los Angeles · USAstellas Pharma (United States) · USOregon Health & Science University · USPfizer (United States) · USUniversity of California, San Diego · USVeterans Health Administration · US

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate CancerR01CA231219 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARONSON, WILLIAM J, COHEN, PINCHAS · 2018 to 2022
$2.1M
IGF-I: A Nutrition-Regulated Target in Prostate CancerR01CA100938 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COHEN, PINCHAS · 2003 to 2007
$1.7M
Midcareer Investigator AwardK24CA160653 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY · 2012 to 2016
$877k
NCI NIH HHS K24 CA160653NCI NIH HHS P50 CA092131NCI NIH HHS R01 CA100938NCI NIH HHS R01 CA231219
6 · The paper itself

Abstract

backgroundIn this study among men who underwent radical prostatectomy (RP), African American men (AAM) were 28% more likely to develop recurrent disease compared with Caucasian men (CM). However, among those who had nonmetastatic, castration-resistant prostate cancer (CRPC), race did not predict metastases or overall survival. Whether race predicts metastases among men who receive androgen-deprivation therapy (ADT) after a biochemical recurrence (BCR) (ie, before CRPC but after BCR) is untested.

methodsThe authors identified 595 AAM and CM who received ADT for a BCR that developed after RP between 1988 and 2015 in the Shared Equal-Access Regional Cancer Hospital (SEARCH) database. Univariable and multivariable Cox models were used to test the association between race and the time from ADT to metastases. Secondary outcomes included the time to CRPC, all-cause mortality, and prostate cancer-specific mortality.

resultsDuring a median follow-up of 66 months after ADT, 62 of 354 CM (18%) and 38 of 241 AAM (16%) developed metastases. AAM were younger at the time they received ADT (63 vs 67 years; P < .001), had received ADT in a more recent year (2008 vs 2006; P < .001), had higher prostate-specific antigen levels at RP (11.1 vs 9.2 ng/mL; P < .001), lower pathologic Gleason scores (P = .004), and less extracapsular extension (38% vs 48%; P = .022). On multivariable analysis, there was no association between race and metastases (hazard radio, 1.20; P = .45) or any of the other secondary outcomes (all P > .5).

conclusionsAmong veterans who received ADT post-BCR after RP, race was not a predictor of metastases or other adverse outcomes. The current findings suggest that research efforts to understand racial differences in prostate cancer biology should focus on early stages of the disease (ie, closer to the time of diagnosis).

Indexed as

Prostatic Neoplasms, Castration-ResistantRacial GroupsAgedAndrogen AntagonistsBiomarkers, TumorBlack or African AmericanDisease ProgressionHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalPrognosisProstatectomyProstate-Specific AntigenTreatment OutcomeAndrogen AntagonistsBiomarkers, TumorProstate-Specific Antigenandrogen-deprivation therapy (ADT)metastasisoutcomesprostate cancerrace

Identifiers

PMID30427535
PMCPMC6340729
OpenAlexW2901724059

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.